{
    "clinical_study": {
        "@rank": "70334", 
        "acronym": "HeHe", 
        "arm_group": [
            {
                "arm_group_label": "Ivy leave", 
                "arm_group_type": "Active Comparator", 
                "description": "active therapy arm with Ivy leave 5 ml twice daily p.o. for four weeks"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Ivy leave placebo 5 ml twice daily p.o. for four weeks"
            }
        ], 
        "brief_summary": {
            "textblock": "The trial aims to record possible effects of a supplementary treatment with ivy leaves dry\n      extract on different lung function parameter, on bronchial hyperreactivity, on individual\n      markers of asthmatic inflammation and on the clinical symptom profile. The hypothesis is,\n      that the additional therapy might improve these parameters and might help to optimize asthma\n      therapy."
        }, 
        "brief_title": "Effect of an add-on Treatment With Ivy Leaves Dry Extract on Lung Function in Bronchial Asthma", 
        "completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Asthma", 
        "condition_browse": {
            "mesh_term": "Asthma"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Medical diagnosis of uncontrolled, mild, persistent, allergic bronchial asthma in\n             terms of the bronchial asthma NVL Version 1.3 (2011)\n\n          2. Children aged from 6 to 12 years (girls and boys)\n\n          3. Signed Informed Consent of the patient and his legal guardians to participate in the\n             trial after written and verbal briefing by the Investigator\n\n          4. Improvement of the FEV1\u226512% after 2 puffs of terbutaline 100 \u00b5g dur-ing steroid\n             monotherapy with 400 \u00b5g budesonide equivalent/day or an ACT score \u2264 19 as an\n             indication of insufficient asthma control\n\n          5. Asthma diagnosis for at least 1 year\n\n        Exclusion Criteria:\n\n          1. Anamnestically known intolerance/allergy to one of the drugs applied or to their\n             ingredients or to drugs of similar chemical structure\n\n          2. Participation of the patient in another clinical trial within the last four weeks\n             before enrollment in this trial\n\n          3. Evidence suggesting that the patient or their legal representative is not likely to\n             follow the trial protocol (e.g. lacking compliance)\n\n          4. Inability to measure lung function, to test bronchospasmolysis, to determine FeNO or\n             to collect exhaled breath condensate, inability to document the symptoms  in a\n             symptom log book or questionnaire; in-ability to take the trial medication properly\n\n          5. Chronic illnesses of different aetiology\n\n          6. Vocal cord dysfunction\n\n          7. Premature birth or diagnosis of bronchopulmonary dysplasia\n\n          8. Gastroesophageal reflux\n\n          9. Acute respiratory infection within the previous 4 weeks\n\n         10. Hereditary fructose intolerance\n\n         11. Pregnant or breastfeeding girls -"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "12 Years", 
            "minimum_age": "6 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 3, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01692041", 
            "org_study_id": "HeHe"
        }, 
        "intervention": [
            {
                "arm_group_label": "Ivy leave", 
                "description": "5 ml twice daily po", 
                "intervention_name": "ivy leaves dry extract", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "5 ml per os twice daily", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "asthma", 
            "children"
        ], 
        "lastchanged_date": "September 24, 2012", 
        "location": {
            "contact": {
                "email": "christian.vogelberg@uniklinikum-dresden.de", 
                "last_name": "Christian Vogelberg, MD PhD", 
                "phone": "0049 351 458", 
                "phone_ext": "2073"
            }, 
            "facility": {
                "address": {
                    "city": "Dresden", 
                    "country": "Germany", 
                    "state": "Saxonia", 
                    "zip": "01307"
                }, 
                "name": "Universit\u00e4tsklinikum Carl Gustav Carus, Kinderklinik"
            }, 
            "investigator": [
                {
                    "last_name": "Christian Vogelberg, MD PhD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Sabine Zeil, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "2", 
        "official_title": "Tolerance and Effect of an add-on Treatment With a Cough Medicine Containing Ivy Leaves Dry Extract on Lung Function in Children With Bronchial Asthma", 
        "overall_contact": {
            "email": "christian.vogelberg@uniklinikum-dresden.de", 
            "last_name": "Christian Vogelberg, MD PhD", 
            "phone": "0049 351 458 2073"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "MEF75-25 will be measured at every time point of the study and relative changes will be followed", 
                "measure": "MEF75-25 before bronchodilation - relative change", 
                "safety_issue": "No", 
                "time_frame": "every 4 weeks"
            }, 
            {
                "description": "FEV1 before bronchodilation will be measured at every study visit and changes will be documented", 
                "measure": "FEV1 before bronchodilation - relative change", 
                "safety_issue": "No", 
                "time_frame": "every 4 weeks"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01692041"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "MEF75-25 before bronchodilation - absolute change", 
                "safety_issue": "No", 
                "time_frame": "every 4 weeks"
            }, 
            {
                "description": "FEV1 before bronchodilation will be measured every visit and changes documented", 
                "measure": "FEV1 before bronchodilation - absolute change", 
                "safety_issue": "No", 
                "time_frame": "every 4 weeks"
            }, 
            {
                "description": "Emergency treatment (beta agonist demand)will be documented daily at home and checked at every study visit", 
                "measure": "Emergency treatment (beta agonist demand)", 
                "safety_issue": "Yes", 
                "time_frame": "daily"
            }, 
            {
                "description": "Number of days with asthma symptoms will be documented daily and checked at every study visit.", 
                "measure": "Number of days with asthma symptoms", 
                "safety_issue": "Yes", 
                "time_frame": "daily"
            }
        ], 
        "source": "Technische Universit\u00e4t Dresden", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Technische Universit\u00e4t Dresden", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2012"
    }
}